Ewing Sarcoma: Radiation Dose and Target Volume

Pediatric Blood and Cancer

Volumn 42, Issue 5, 2004, Pages 471-476

  Donaldson, Sarah S ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ewing sarcoma; Local control; Radiation dose; Radiation volume

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; RAPAMYCIN; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; DOSIMETRY; EWING SARCOMA; HUMAN; INTRAOPERATIVE PERIOD; IRRADIATION; LOCAL THERAPY; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION FIELD; SURVIVAL RATE; TUMOR VOLUME;

CHILD; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MAGNETIC RESONANCE IMAGING; RADIOTHERAPY DOSAGE; SARCOMA, EWING'S; TREATMENT OUTCOME;

EID: 1942486923     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.10472     Document Type: Conference Paper

References (15)

1. Marcus RB, Jr., Berrey BH, Graham-Pole J, et al. The treatment of Ewing's sarcoma of bone at the University of Florida: 1969 to 1998. Clin Orthop 2002;397:290-297.
2. Ahrens S, Hoffmann C, Jabar S, et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999;32:186-195.
3. Nesbit ME, Jr., Gehan EA, Burgert EO, Jr., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-1674.
4. Burgert EO, Jr., Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990;8:1514-1524.
5. Dunst J, Jurgens H, Sauer R, et al. Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;32:919-930.
6. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998;16:3628-3633.
7. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168-177.
8. Bacci G, Toni A, Avella M, et al. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 1989;63:1477-1486.
9. Arai Y, Kun LE, Brooks MT, et al. Ewing's sarcoma: Local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:1501-1508.
10. Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: End results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:125-135.
11. Marcus RB, Jr., Cantor A, Heare TC, et al. Local control and function after twice-a-day radiotherapy for Ewing's sarcoma of bone. Int J Radiat Oncol Biol Phys 1991;21:1509-1515.
12. Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: A preliminary report of 6 years of experience. Cancer 1999;86:421-428.
13. Schuck A, Rube C, Konemann S, et al. Postoperative radiotherapy in the treatment of Ewing tumors: Influence of the interval between surgery and radiotherapy. Strahlenther Onkol 2002;178:25-31.
14. Calvo FA, Ortiz de Urbina D, Sierrasesumaga L, et al. Intraoperative radiotherapy in the multidisciplinary treatment of bone sarcomas in children and adolescents. Med Pediatr Oncol 1991;19:478-485.
15. Isacsson U, Hagberg H, Johansson KA, et al. Potential advantages of protons over conventional radiation beams for paraspinal tumours. Radiother Oncol 1997;45:63-70.